Algen Biotechnologies vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI drug discovery platform mapping functional gene networks for novel target identification; $12.63M from Viking Global and YC W20 applying computational genomics to decode disease biology.
About
Algen Biotechnologies is a San Francisco-based drug discovery company that builds computational platforms to decode functional gene networks — using machine learning and genomic data to map the relationships between genes, understand how gene interactions drive disease, and identify novel therapeutic targets that traditional drug discovery approaches miss because they analyze genes in isolation. Founded in 2018 by Chun Hao Huang and Christine Du and a Y Combinator W20 graduate, Algen raised $12.63 million total including a $9 million Seed VC-II round led by Viking Global Investors in February 2022.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.